Search results for "VEGF"

showing 8 items of 148 documents

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.

2013

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

medicine.medical_specialtyRetinal Veingenetic structuresReviewlaw.inventionRandomized controlled triallcsh:OphthalmologylawOphthalmologyOcclusionMedicineIn patientranibizumabMacular edemaIntravitreal triamcinolonemacular edemabusiness.industrymedicine.diseaseVEGFeye diseasesantiangiogenic therapylcsh:RE1-994retinal vein occlusionRetinal vein occlusionsRanibizumabbusinessBiomedical engineeringmedicine.drugOphthalmology and eye diseases
researchProduct

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

2013

Pasi Vottonen,1 Kai Kaarniranta,1,2 Ari Pääkkönen,3 Ina M Tarkka41Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 3Department of Clinical Neurophysiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Health Sciences, University of Jyväskylä, Jyväskylä, FinlandPurpose: Antivascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration. As the vision im…

medicine.medical_specialtyVisual acuityexudative age-related macular degenerationvisual acuitygenetic structuresvisual evoked potentialsVEGF receptorsta3112Cortical processingVisual processingText miningOphthalmologymedicinescalp-recorded EEGage-related eye diseasesOriginal Researchbiologybusiness.industryta3141Clinical OphthalmologyMacular degenerationmedicine.diseaseeye diseasesOphthalmologybiology.proteinElectrophysiological markerssense organsAnti vegf treatmentmedicine.symptombusinessClinical Ophthalmology
researchProduct

Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for C…

2019

The study&rsquo

medicine.medical_specialtyYounger agegenetic structuresmedicine.medical_treatmentvitrectomyVitrectomytractional macular detachmentArticle03 medical and health sciences0302 clinical medicineOphthalmologymedicine030212 general & internal medicineanti-VEGF; proliferative diabetic retinopathy; tractional macular detachment; vitrectomyAnti vegfbusiness.industryPrimary vitrectomyIncidence (epidemiology)General MedicineDiabetic retinopathymedicine.diseaseeye diseasesMacular detachmentanti-VEGFVitreous hemorrhage030221 ophthalmology & optometrysense organsbusinessproliferative diabetic retinopathyJournal of Clinical Medicine
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Angiogenic and/or pro-apoptotic factors are shed from brain cells via extracellular vesicles

2008

We set a three-cell type coculture system in which neurons and astrocytes synergistically induce brain capillary endothelial cells to form a monolayer with permeability properties resembling those of the physiological blood-brain barrier (BBB) (Schiera et al., 2003; Schiera et al., 2005). On the basis of immunofluorescence, scanner electron microscopy and western blot analyses, we also suggested that both astrocytes and neurons in culture shed extracellular vesicles that contain FGF-2 and VEGF, as well as beta1-integrin, a membrane protein that can be considered a marker of shedding (Schiera et al, 2007; Proia et al., 2008). In addition, it was already known that transformed glial cells (ol…

membrane vesicle sheddingSettore BIO/10 - BiochimicaFGF-2TRAILTGF-betaVEGF
researchProduct

Audzēja ekstracelulāro vezikulu loma mezenhimālo cilmes šūnu sekrēcijas profila izmaiņās

2017

Ekstarcelulārās vezikulas ir mazi pūslīši, kas tiek atbrīvoti no šūnām un izlaisti starpšūnu vidē. EV satur saimniekšūnu ģenētisko materiālu vai to daļas un caur tām viena šūna var nodot informācijas signālu otrai šūnai, tādā veidā ietekmējot to darbību. Arī vēža šūnas var atbrīvot šādas vezikulas un iedarboties uz blakusesošajām gan saimniekorganisma šūnām, gan pašām vēža šūnām. Caur šādu komunikāciju vēža šūnas var pārnest savu izmainīto ģenētisko materiālu uz normālajām šūnām un pārregulēt to darbības mehānismus, kas darbotos audzēja šūnu labā. Darba mērķis bija noskaidrot vai audzēja EV var izraisīt IL-8 un VEGF sekrēcijas izmaiņas ādas mezenhimālajās cilmes šūnās. Lai to noskaidrotu, I…

mesenchymal stem cellsIL-8FarmācijaaudzējsVEGFmezenhimālās cilmes šūnas
researchProduct

Angiogenesis control in spine regeneration

2012

Abstract: The intervertebral disc (IVD) has a complex vascularisation pattern. While the nucleus pulposus is avascular, the annulus fibrosus as well as the endplates are vascularised. IVD degeneration is often accompanied, on the one hand, by blood vessel ingrowth into the nucleus pulposus and, on the other hand, by diminished vascularisation of the endplates. Tissue engineering of IVD, therefore, has to address the differences in the vascularisation of IVD compartments. This chapter summarises current knowledge about the mechanisms of angiogenesis and its physiological and pathological role in IVD biology. Different strategies to control angiogenesis are discussed in the chapter with examp…

musculoskeletal diseasesAngiogenesisRegeneration (biology)VEGF receptorsIntervertebral discAnatomyDegeneration (medical)Biologymusculoskeletal systemBone tissue engineeringmedicine.anatomical_structureTissue engineeringotorhinolaryngologic diseasesmedicinebiology.proteinsense organsBlood vessel
researchProduct

Is Saffron Able to Prevent the Dysregulation of Retinal Cytokines Induced by Ocular Hypertension in Mice?

2021

Cytokine- and chemokine-mediated signalling is involved in the neuroinflammatory process that leads to retinal ganglion cell (RGC) damage in glaucoma. Substances with anti-inflammatory properties could decrease these cytokines and chemokines and thus prevent RGC death. The authors of this study analysed the anti-inflammatory effect of a hydrophilic saffron extract standardized to 3% crocin content, focusing on the regulation of cytokine and chemokine production, in a mouse model of unilateral laser-induced ocular hypertension (OHT). We demonstrated that following saffron treatment, most of the concentration of proinflammatory cytokines (IL-1β, IFN-γ, TNF-α, and IL-17), anti-inflammatory cyt…

retinal glial cellsChemokinegenetic structuresmedicine.medical_treatmentNeurocienciasmicrogliasaffronInflammationPharmacologyArticleProinflammatory cytokineCrocinchemistry.chemical_compoundfractalkineNeurotrophic factorsMedicineFisiología animalbiologyMicrogliabusiness.industryRGeneral MedicineVEGFcytokineseye diseasescrocinVascular endothelial growth factorBDNFglaucomamedicine.anatomical_structureCytokinechemistrybiology.proteinocular hypertensionMedicineOftalmologíaOftalmología veterinariasense organsmedicine.symptombusinessJournal of clinical medicine
researchProduct